Cargando…

Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy

To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 relaxation...

Descripción completa

Detalles Bibliográficos
Autores principales: Luetkens, Julian A., Wolpers, Anne C., Beiert, Thomas, Kuetting, Daniel, Dabir, Darius, Homsi, Rami, Meendermann, Hendrik, Dayé, Natalie Abou, Knappe, Vincent, Karsdal, Morten, Nielsen, Signe H., Genovese, Federica, Stöckigt, Florian, Linhart, Markus, Thomas, Daniel, Nickenig, Georg, Schild, Hans H., Schrickel, Jan W., Andrié, René P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134059/
https://www.ncbi.nlm.nih.gov/pubmed/30206274
http://dx.doi.org/10.1038/s41598-018-31916-2
_version_ 1783354603796955136
author Luetkens, Julian A.
Wolpers, Anne C.
Beiert, Thomas
Kuetting, Daniel
Dabir, Darius
Homsi, Rami
Meendermann, Hendrik
Dayé, Natalie Abou
Knappe, Vincent
Karsdal, Morten
Nielsen, Signe H.
Genovese, Federica
Stöckigt, Florian
Linhart, Markus
Thomas, Daniel
Nickenig, Georg
Schild, Hans H.
Schrickel, Jan W.
Andrié, René P.
author_facet Luetkens, Julian A.
Wolpers, Anne C.
Beiert, Thomas
Kuetting, Daniel
Dabir, Darius
Homsi, Rami
Meendermann, Hendrik
Dayé, Natalie Abou
Knappe, Vincent
Karsdal, Morten
Nielsen, Signe H.
Genovese, Federica
Stöckigt, Florian
Linhart, Markus
Thomas, Daniel
Nickenig, Georg
Schild, Hans H.
Schrickel, Jan W.
Andrié, René P.
author_sort Luetkens, Julian A.
collection PubMed
description To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 relaxation times were assessed using CMR. Plasma levels of relaxin, myeloperoxidase and serum levels of matrix metalloproteinase (MMP)-mediated cardiac specific titin fragmentation and MMP-mediated type IV collagen degradation were obtained. Poor outcome was defined by the recurrence of AF during 1-year follow-up. 61 patients were included in final analysis. Twenty (32.8%) patients had recurrence of AF. Patients with a recurrence of AF had a higher percentage of LA LGE (26.7 ± 12.5% vs. 17.0 ± 7.7%; P < 0.001), higher LA T1 relaxation times (856.7 ± 112.2 ms vs. 746.8 ± 91.0 ms; P < 0.001) and higher plasma levels of relaxin (0.69 ± 1.34 pg/ml vs. 0.37 ± 0.88 pg/ml; P = 0.035). In the multivariate Cox regression analysis, poor ablation outcome was best predicted by advanced LGE stage (hazard ratio (HR):5.487; P = 0.001) and T1 relaxation times (HR:1.007; P = 0.001). Pre-procedural CMR is a valuable tool for prediction of poor response to catheter ablation therapy in patients with AF. It offers various imaging techniques for outcome prediction and might be valuable for a better patient selection prior to ablation therapy.
format Online
Article
Text
id pubmed-6134059
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-61340592018-09-15 Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy Luetkens, Julian A. Wolpers, Anne C. Beiert, Thomas Kuetting, Daniel Dabir, Darius Homsi, Rami Meendermann, Hendrik Dayé, Natalie Abou Knappe, Vincent Karsdal, Morten Nielsen, Signe H. Genovese, Federica Stöckigt, Florian Linhart, Markus Thomas, Daniel Nickenig, Georg Schild, Hans H. Schrickel, Jan W. Andrié, René P. Sci Rep Article To determine the pre-procedural value of different fibrotic biomarkers and comprehensive cardiac magnetic resonance (CMR) for the prediction of poor response to ablation therapy in patients with atrial fibrillation (AF). Left atrial (LA) late gadolinium enhancement (LGE) and native LA T1 relaxation times were assessed using CMR. Plasma levels of relaxin, myeloperoxidase and serum levels of matrix metalloproteinase (MMP)-mediated cardiac specific titin fragmentation and MMP-mediated type IV collagen degradation were obtained. Poor outcome was defined by the recurrence of AF during 1-year follow-up. 61 patients were included in final analysis. Twenty (32.8%) patients had recurrence of AF. Patients with a recurrence of AF had a higher percentage of LA LGE (26.7 ± 12.5% vs. 17.0 ± 7.7%; P < 0.001), higher LA T1 relaxation times (856.7 ± 112.2 ms vs. 746.8 ± 91.0 ms; P < 0.001) and higher plasma levels of relaxin (0.69 ± 1.34 pg/ml vs. 0.37 ± 0.88 pg/ml; P = 0.035). In the multivariate Cox regression analysis, poor ablation outcome was best predicted by advanced LGE stage (hazard ratio (HR):5.487; P = 0.001) and T1 relaxation times (HR:1.007; P = 0.001). Pre-procedural CMR is a valuable tool for prediction of poor response to catheter ablation therapy in patients with AF. It offers various imaging techniques for outcome prediction and might be valuable for a better patient selection prior to ablation therapy. Nature Publishing Group UK 2018-09-11 /pmc/articles/PMC6134059/ /pubmed/30206274 http://dx.doi.org/10.1038/s41598-018-31916-2 Text en © The Author(s) 2018 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Luetkens, Julian A.
Wolpers, Anne C.
Beiert, Thomas
Kuetting, Daniel
Dabir, Darius
Homsi, Rami
Meendermann, Hendrik
Dayé, Natalie Abou
Knappe, Vincent
Karsdal, Morten
Nielsen, Signe H.
Genovese, Federica
Stöckigt, Florian
Linhart, Markus
Thomas, Daniel
Nickenig, Georg
Schild, Hans H.
Schrickel, Jan W.
Andrié, René P.
Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title_full Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title_fullStr Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title_full_unstemmed Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title_short Cardiac magnetic resonance using late gadolinium enhancement and atrial T1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
title_sort cardiac magnetic resonance using late gadolinium enhancement and atrial t1 mapping predicts poor outcome in patients with atrial fibrillation after catheter ablation therapy
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6134059/
https://www.ncbi.nlm.nih.gov/pubmed/30206274
http://dx.doi.org/10.1038/s41598-018-31916-2
work_keys_str_mv AT luetkensjuliana cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT wolpersannec cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT beiertthomas cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT kuettingdaniel cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT dabirdarius cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT homsirami cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT meendermannhendrik cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT dayenatalieabou cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT knappevincent cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT karsdalmorten cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT nielsensigneh cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT genovesefederica cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT stockigtflorian cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT linhartmarkus cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT thomasdaniel cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT nickeniggeorg cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT schildhansh cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT schrickeljanw cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy
AT andrierenep cardiacmagneticresonanceusinglategadoliniumenhancementandatrialt1mappingpredictspooroutcomeinpatientswithatrialfibrillationaftercatheterablationtherapy